The Sound of Evolution
Etanercept
Mechanism of action:
Etanercept is a tumor necrosis factor inhibitor and a soluble TNF receptor-Fc fusion protein. Etanercept is composed of the extracellular domain of the human tumor necrosis factor receptor p75 (TNFR2) fused to the Fc portion of IgG1. It binds with high affinity to TNF-α and TNF-β (lymphotoxin-α), preventing TNF from binding to cell surface TNF receptors. This suppresses downstream inflammatory signaling and inhibits pathways involved in the induction and release of inflammatory cytokines such as IL-1 and IL-6, as well as chemokines.
Reference(s):
1. Hofmann HP et al. (2016). Characterization and non-clinical assessment of the proposed etanercept biosimilar GP2015 with originator etanercept (Enbrel®). Expert Opin Biol Ther.
2. Zhou SY et al. (2011). Integrated population pharmacokinetics of etanercept in healthy subjects and in patients with rheumatoid arthritis and ankylosing spondylitis. J Clin Pharmacol.